Vaccines
Quadrivalent recombinant influenza vaccine
Brand: Flublok® Quadrivalent
PBAC's latest decision on Quadrivalent recombinant influenza vaccine: Recommended (2024). Considered for Prevention of influenza in people aged 65 years and over.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2024 → 2024
Eligible population Adults aged 65 years and over for the prevention of influenza.
Therapy area Vaccines Line of therapy Not applicable Evidence base RCT Primary endpoint Relative vaccine effectiveness (rVE), influenza hospital encounters, influenza inpatient stays Pivotal trial size 12,800,000 patients Key trials Izurieta 2021, Izurieta 2020, Belongia et al. 2020, Cowling et al. 2020, Essink et al. 2020 Comparator adjuvanted egg-based quadrivalent influenza vaccine (aQIV, Fluad® Quad) Economic model Cost-minimisation ICER note Cost-consequence analysis conducted; no ICER calculated as this is a vaccine submission with cost-minimisation/cost-consequence framework. Similar precedents
Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.